ArticleCureus2025
Severe Late-Onset Neutropenia in a Patient With Multiple Sclerosis Treated With Ocrelizumab.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocrelizumab, a humanised monoclonal antibody targeting cluster of differentiation 20 (CD20), is widely used to treat multiple sclerosis (MS). While it is effective in reducing relapse rates, adverse effects such as late-onset neutropenia can pose significant clinical challenges. We report the case of a 36-year-old female with a history of relapsing-remitting MS (RRMS) who developed severe neutropenia following ocrelizumab administration. The patient presented with fever, fatigue, and oral aphthous ulcers, with laboratory tests confirming an absolute neutrophil count (ANC) of 0.11 × 10⁹/L. Prompt initiation of broad-spectrum antibiotics and granulocyte colony-stimulating factor (G-CSF) resulted in significant clinical improvement. This case highlights the importance of monitoring blood counts in patients receiving ocrelizumab and the need for timely intervention for late-onset neutropenia (LON).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.